Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrew J Brenner, PhD
The Cancer Therapy and Research Center at UTHSCSA
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Northshore University Hospital
Manhasset, New York, United States
Michael Schulder, MD, FAANSRecruiting - Ut Southwestern Medical Center
Dallas, Texas, United States
Toral Patel, MDRecruiting - the Cancer Therapy and Research Center at Uthscsa
San Antonio, Texas, United States
Andrew J Brenner, M.D., Ph.D.John R Floyd, M.D.William T Phillips, M.D.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Jun 2015
- Primary completion
- 31 Dec 2025
- Completion
- 31 Dec 2025
- Last update posted
- 26 Mar 2025
- Registered enrollment
- 55
- Registry id
- NCT01906385
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.